Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galaxy MedicareNSE:GML 20 3-Year EBITDA Growth Rate is 11.10% as of Mar. 2026, which is 61% below its 10-year median of 28.15. GuruFocus rates NSE:GML with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Galaxy Medicare ranks better than 53.05% on this metric.
During the past 12 months, Galaxy Medicare's average EBITDA Per Share Growth Rate was -1.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Galaxy Medicare was 45.20% per year. The lowest was 11.10% per year. And the median was 28.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Galaxy Medicare 3-Year EBITDA Growth Rate Related Terms
NSE:GML vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Galaxy Medicare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galaxy Medicare 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Galaxy Medicare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Galaxy Medicare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.10% mean?
Galaxy Medicare (NSE:GML) has a 3-Year EBITDA Growth Rate of 11.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Galaxy Medicare and its competitors. This is 61% below median its historical median of 28.15. Over the past decade, Galaxy Medicare's 3-Year EBITDA Growth Rate has ranged from 11.10 to 45.20. According to the industry distribution chart, Galaxy Medicare ranks #323 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 46.9%.
Is Galaxy Medicare's 3-Year EBITDA Growth Rate too high?
Galaxy Medicare's current 3-Year EBITDA Growth Rate of 11.10% is 61% below median its 10-year median of 28.15. Over the past 10 years, this metric has ranged from a low of 11.10 to a high of 45.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.90. Galaxy Medicare's value of 11.10% is 40.5% above this industry median. Based on the distribution chart, Galaxy Medicare ranks #323 out of 688 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Galaxy Medicare has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Galaxy Medicare's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Galaxy Medicare ranks #323 out of 688 companies for 3-Year EBITDA Growth Rate. This puts Galaxy Medicare in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.90. Galaxy Medicare's value of 11.10% is 40.5% above this benchmark. Historically, Galaxy Medicare's own 3-Year EBITDA Growth Rate has ranged from 11.10 to 45.20 over the past decade. While the company's 10-year median is 28.15 vs. the industry median of 7.90, Galaxy Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galaxy Medicare's current 3-Year EBITDA Growth Rate of 11.10% is 40.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Galaxy Medicare and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galaxy Medicare's current 3-Year EBITDA Growth Rate is 11.10%, which is 61% below median its own 10-year median of 28.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galaxy Medicare stock overvalued right now?
Galaxy Medicare (NSE:GML) has a current 3-Year EBITDA Growth Rate of 11.10%. The current 3-Year EBITDA Growth Rate is 11.10%, which is 61% below median its 10-year median of 28.15 and 40.5% above the Medical Devices & Instruments industry median of 7.90. Galaxy Medicare's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Galaxy Medicare (NSE:GML), the current 3-Year EBITDA Growth Rate is 11.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galaxy Medicare Ltd is engaged into the manufacturing, trading and exporting of Medical Devices, Plasters of Paris Bandages (POP Bandage) and Other surgical dressings in India. Its business encompass: Manufacturing and Branding of its own products under its flagship brands i.e. POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE GYPSONET, GYPSOCHLOR, FIXCAN ETC.
20GF Score
Get the complete analysis for NSE:GML
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GML has been successfully added to your 
